about
Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexProduction of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vectorVaccines in development against West Nile virusExperimental infection of rhesus macaques and common marmosets with a European strain of West Nile virusImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesA Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple FormulationsVaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virusNewcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultryPathogenesis of West Nile Virus Infection: a Balance between Virulence, Innate and Adaptive Immunity, and Viral EvasionVaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Declining Growth Rate of West Nile Virus in North AmericaCurrent Status of Veterinary VaccinesComplex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.West Nile Virus-Induced Neuroinflammation: Glial Infection and Capsid Protein-Mediated NeurovirulenceComparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis ModelInduction of Epitope-Specific Neutralizing Antibodies against West Nile VirusIdentification of Mutated Cyclization Sequences That Permit Efficient Replication of West Nile Virus Genomes: Use in Safer Propagation of a Novel Vaccine CandidateThe relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virusTumor Necrosis Factor Alpha Protects against Lethal West Nile Virus Infection by Promoting Trafficking of Mononuclear Leukocytes into the Central Nervous SystemEvaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeysClosing the door on flaviviruses: Entry as a target for antiviral drug designA recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cellsEvaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamstersRecombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus MacaquesPlant-made vaccines against West Nile virus are potent, safe, and economically feasibleVero cell platform in vaccine production: moving towards cell culture-based viral vaccines.Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal deliveryInfection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strainNorth American encephalitic arbovirusesEvaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection.Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoeliiPhase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adultsViscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccinationCurrent trends in West Nile virus vaccine development.Immune responses to an attenuated West Nile virus NS4B-P38G mutant strain.Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling.
P2860
Q24737461-1A5C236E-7B5D-411F-990B-4DECC8872396Q26247032-96BCF5FB-0A0A-459B-A388-F57B4BCAC1AFQ26999702-09D2F0C9-7F72-40B0-A7DB-81A39C582E85Q27304916-F32B539C-022B-4DA3-9732-DC688E643042Q27319783-72146477-4A64-41DE-A9D4-EC91DAAF92FEQ27321020-01495A2E-C08A-46DC-8166-3440CF15F717Q27329490-A8DB28B5-C587-4F2C-B82D-883229448D2EQ27469028-22C585EF-28F0-4B7A-970C-E03F959D681BQ27477543-D5A7719F-3CF3-46EB-9F46-9BCB52E12229Q27478162-39B59A8C-E936-4DD3-BDFF-2AF32E4B5A9EQ27478364-36A1DF74-94D7-4126-A4FC-E1931DB03715Q27480923-BE55CD48-63E0-44BB-988A-0121AF63A36EQ27481420-D9612C03-B4E7-43CA-9EA4-43F2523E070EQ27481490-F42B3B36-2699-451B-B3B5-E850B03B0EC3Q27484655-7DAC93B9-1A37-4D16-97B7-5F4E3EBC501EQ27484980-96675E8D-3EDC-4313-8976-985A936E4578Q27486407-70FA66E7-26B6-4260-8758-E0EC302D615EQ27486421-830DD8EA-267A-466F-A456-2EFBA52CA70DQ27486917-79026FC4-AAD8-4B8E-9D8C-D3CB1E203EA4Q27487013-D468F937-BA3E-4DA9-A94A-480C2A87D4E2Q27487953-714F2E23-6E6D-4051-92F7-AE518F7FDCBCQ27487992-B1E7F336-EE7F-4154-9A98-6E083982A605Q27490208-22A7E95E-6613-4292-A23C-DFA86D0EAEBFQ27491052-B360BB14-4049-46FB-A392-6F76E40D0E59Q28082778-18033E82-161F-4949-8CF1-C1D2825BC614Q30376550-99454CCA-01F9-4F25-88E2-7B7B9C15E3F7Q33584872-7B52F818-71EA-44C3-940C-4C88C8D37434Q33820714-D78510FC-AC20-41CA-B3D8-B51BD4CBE5C3Q33835377-AAA058F8-3502-401D-9711-96BC2D3BAAD8Q33880730-E4EE1AD0-5563-4C97-B2F2-42F78FE29A83Q33909344-04237BA6-83E8-44E3-9151-89C1C74EF14FQ33992835-C9505C4C-E501-4889-A05F-EBD240D4CBF5Q34039347-0D7DEE2C-91FB-4D94-84EF-97F7B6C8F371Q34109763-8A9C72E1-F0BD-4E99-BD7F-2A69DF5605AAQ34154300-45AD4E52-EDB7-4D89-A69D-95DBABEB10FFQ34258885-421CBCBC-68EB-4AB3-A6A7-4DE98E35BF13Q34764414-3C435BB5-F294-48C0-BF39-3BD7F2EE37EFQ34788758-6FCC5C94-0AD9-4E63-8DF3-80709BF9C944Q35042669-24C802EE-C279-42ED-95D5-4F42B67B95EFQ35742553-A806795A-47E7-41AE-8D2C-9C4FFFB5E5B8
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A live, attenuated recombinant West Nile virus vaccine
@nl
A live, attenuated recombinant West Nile virus vaccine.
@ast
A live, attenuated recombinant West Nile virus vaccine.
@en
type
label
A live, attenuated recombinant West Nile virus vaccine
@nl
A live, attenuated recombinant West Nile virus vaccine.
@ast
A live, attenuated recombinant West Nile virus vaccine.
@en
prefLabel
A live, attenuated recombinant West Nile virus vaccine
@nl
A live, attenuated recombinant West Nile virus vaccine.
@ast
A live, attenuated recombinant West Nile virus vaccine.
@en
P2093
P2860
P3181
P356
P1476
A live, attenuated recombinant West Nile virus vaccine.
@en
P2093
Casey Johnson
Francis A Ennis
Gwendolyn A Myers
Jeffrey S Kennedy
Juan Arroyo
Karen McCarthy
Niranjan Kanesa-Thasan
Philip Bedford
Richard Nichols
P2860
P304
P3181
P356
10.1073/PNAS.0601932103
P407
P577
2006-04-14T00:00:00Z